Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $17,728 | 7 | 99.2% |
| Food and Beverage | $144.79 | 2 | 0.8% |
Payments by Type
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $14,401 | 6 | $0 (2023) |
| Biohaven Pharmaceuticals, Inc. | $3,327 | 1 | $0 (2021) |
| UCB, Inc. | $124.99 | 1 | $0 (2018) |
| Purdue Pharma L.P. | $19.80 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $14,401 | 6 | PFIZER INC. ($14,401) |
| 2021 | $3,327 | 1 | Biohaven Pharmaceuticals, Inc. ($3,327) |
| 2018 | $124.99 | 1 | UCB, Inc. ($124.99) |
| 2017 | $19.80 | 1 | Purdue Pharma L.P. ($19.80) |
All Payment Transactions
9 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/14/2023 | PFIZER INC. | ZAVZPRET (Drug) | — | Cash or cash equivalent | $1,424.19 | Research |
| Study: A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION • Category: PAIN | ||||||
| 10/12/2023 | PFIZER INC. | ZAVZPRET (Drug) | — | Cash or cash equivalent | $1,797.78 | Research |
| Study: A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION • Category: PAIN | ||||||
| 09/21/2023 | PFIZER INC. | ZAVZPRET (Drug) | — | Cash or cash equivalent | $1,424.19 | Research |
| Study: A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION • Category: PAIN | ||||||
| 08/30/2023 | PFIZER INC. | ZAVZPRET (Drug) | — | Cash or cash equivalent | $1,424.19 | Research |
| Study: A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION • Category: PAIN | ||||||
| 05/25/2023 | PFIZER INC. | ZAVZPRET (Drug) | — | Cash or cash equivalent | $5,016.30 | Research |
| Study: A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION • Category: PAIN | ||||||
| 05/25/2023 | PFIZER INC. | ZAVZPRET (Drug) | — | Cash or cash equivalent | $3,314.29 | Research |
| Study: A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION • Category: PAIN | ||||||
| 01/27/2021 | Biohaven Pharmaceuticals, Inc. | — | — | Cash or cash equivalent | $3,327.10 | Research |
| Study: Double-Blind Randomized Placebo Controlled Safety and Efficacy Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine | ||||||
| 03/09/2018 | UCB, Inc. | — | Food and Beverage | In-kind items and services | $124.99 | General |
| 04/25/2017 | Purdue Pharma L.P. | HYSINGLA ER (Drug), BUTRANS, OXYCONTIN | Food and Beverage | Cash or cash equivalent | $19.80 | General |
| Category: PAIN MANAGEMENT | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION | PFIZER INC. | $14,401 | 6 |
| Double-Blind Randomized Placebo Controlled Safety and Efficacy Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine | Biohaven Pharmaceuticals, Inc. | $3,327 | 1 |
About Dr. Steve Wheeler, M.D
Dr. Steve Wheeler, M.D is a Neurology healthcare provider based in South Miami, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/11/2006. The National Provider Identifier (NPI) number assigned to this provider is 1629138359.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Steve Wheeler, M.D has received a total of $17,873 in payments from pharmaceutical and medical device companies, with $14,401 received in 2023. These payments were reported across 9 transactions from 4 companies. The most common payment nature is "" ($17,728).
Practice Information
- Specialty Neurology
- Location South Miami, FL
- Active Since 12/11/2006
- Last Updated 07/08/2007
- Taxonomy Code 2084N0400X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1629138359
Products in Payments
- ZAVZPRET (Drug) $14,401
- HYSINGLA ER (Drug) $19.80
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in South Miami
Dr. Javier Lopez, Md, MD
Neurology — Payments: $37,876
Dr. Christopher Jimenez, M.d, M.D
Neurology — Payments: $20,037
Dr. Simon Starosta-Rubinstein, Md, MD
Neurology — Payments: $17,455
Ajay Pandey, M.d, M.D
Neurology — Payments: $15,568
Dr. Victor Barredo, M.d, M.D
Neurology — Payments: $14,641
Dr. Paul Damski, Md, MD
Neurology — Payments: $7,933